HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Biagi, E. Articles by Biondi, A. Search for Related Content PubMed PubMed Citation Articles by Biagi, E. Articles by Biondi, A.

Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies

"Centro di Ricerca Matilde Tettamanti", Department of Paediatrics, University of Milano-Bicocca, San Gerardo Hospital, Monza, Milan, Italy.

Correspondence: Ettore Biagi, Centro di Ricerca "M. Tettamanti", Clinica Pediatrica Università Milano-Bicocca, Via Pergolesi 33, 20052 Monza. E-mail: ettore.biagi{at}pediatriamonza.it

Chimeric T-cell receptors (ChTCR) are a fascinating technological step in the field of immunotherapy for orienting the activity of immune cells towards specific molecular targets expressed on the cell surface of various tumors, including hematologic malignancies. The main characteristics of ChTCR are their ability to redirect T-cell specificity and their killing/effector activity toward a selected target in a non-MHC-restricted manner, exploiting the antigen binding properties of monoclonal antibodies. ChTCR are, in fact, artificial T-cell receptors constituted by an antigen-recognizing antibody molecule linked to a T-cell triggering domain. Various hematologic malignancies represent optimal targets for the exploitation of ChTCR, because of the bright expression of specific antigens on the surface of tumor cells. Thus, CD19 and CD20 have been targeted for B-cell lymphoid tumors (acute lymphoblastic leukemia-ALL, lymphomas and chronic lymphocytic leukemia-CLL), CD33 for myeloid leukemia, and CD30 for lymphomas. Even though technical and safety progresses are still needed to improve the profile of gene transfer and protein expression of ChTCR, phase 1 trials will be carried out in the near future to demonstrate the feasibility of their clinical translation and, it is be hoped, give preliminary indications about their anti-tumor efficacy.

Key words: chimeric T-cell receptor, immunotherapy, hematologic malignancy.

This article has been cited by other articles:

				D. Bagnara, A. Ibatici, M. Corselli, N. Sessarego, C. Tenca, A. De Santanna, A. Mazzarello, A. Daga, R. Corvo, G. De Rossi, et al. Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms Haematologica, July 1, 2009; 94(7): 967 - 974. [Abstract] [Full Text] [PDF]